0000899243-19-008692.txt : 20190321 0000899243-19-008692.hdr.sgml : 20190321 20190321170018 ACCESSION NUMBER: 0000899243-19-008692 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190320 FILED AS OF DATE: 20190321 DATE AS OF CHANGE: 20190321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: IVERS-READ GILLIAN C CENTRAL INDEX KEY: 0001268304 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 19697626 MAIL ADDRESS: STREET 1: C/O PHARMION CORPORATION STREET 2: 2525 28TH STREET CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-20 0 0001466301 Clovis Oncology, Inc. CLVS 0001268304 IVERS-READ GILLIAN C C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2019-03-20 4 M 0 1875 A 190837 D Common Stock 2019-03-20 4 S 0 830 26.13 D 190007 D Restricted Stock Units 2019-03-20 4 M 0 1875 0.00 D Common Stock 1875 13125 D Each Restricted Stock Unit represents the right to receive one share of Common Stock. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. On December 19, 2016, the reporting person was granted 30,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Executive Vice President of Technical Operations and Chief Regulatory Officer /s/ Gillian C. Ivers-Read 2019-03-21